Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Vikas-Gupta"

14 News Found

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
News | July 05, 2023

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio

IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
News | May 01, 2023

IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr

Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

Top management changes at IOL Chemicals and Pharmaceuticals
People | April 04, 2023

Top management changes at IOL Chemicals and Pharmaceuticals

Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company

Lilly to transfer rights of two diabetes drugs to Cipla in India
Drug Approval | October 04, 2021

Lilly to transfer rights of two diabetes drugs to Cipla in India

Lilly will continue to maintain its existing operating model for the remaining portfolio of products

Latest Stories

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging